8-KMaterial AgreementsOther EventsExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Material Agreement (Nov 1, 2023)

Filed November 1, 2023For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) has filed a Form 8-K to report on the issuance of $750 million aggregate principal amount of 6.400% senior notes due 2033. This debt offering, priced on October 30, 2023, and issued on November 1, 2023, aims to raise capital for the company. The notes are senior unsecured obligations and will rank equally with existing and future senior unsecured debt. The issuance was conducted under the company's shelf registration statement and involved an underwriting agreement with several prominent financial institutions. This filing indicates a strategic move by Quest Diagnostics to secure long-term financing. Investors should note the coupon rate of 6.400% and the maturity date of November 30, 2033. The indenture includes covenants that may restrict certain actions by the company and its subsidiaries, such as creating liens or engaging in sale and leaseback transactions, and also contains provisions for a mandatory repurchase offer at 101% of principal in the event of a change of control triggering event.

Key Highlights

  • 1Quest Diagnostics issued $750 million in 6.400% senior notes due 2033.
  • 2The notes were priced on October 30, 2023, and issued on November 1, 2023.
  • 3The debt is senior unsecured and ranks equally with other senior unsecured obligations.
  • 4The offering was made under the company's existing shelf registration statement.
  • 5The indenture includes covenants limiting liens, sale and leaseback transactions, and debt at non-guarantor subsidiaries.
  • 6A change of control triggering event requires the company to offer to repurchase the notes at 101% of principal.
  • 7The issuance represents a significant capital raise for Quest Diagnostics.

Frequently Asked Questions

This 8-K filing announces that Quest Diagnostics has entered into a material definitive agreement, specifically the issuance of $750 million in senior notes due 2033. It details the terms of the debt offering, including interest rate, maturity date, and covenants.

The new notes have an aggregate principal amount of $750 million, bear a fixed interest rate of 6.400% per annum, and mature on November 30, 2033. Interest is paid semi-annually on May 30 and November 30, starting May 30, 2024.

The notes are senior unsecured obligations of Quest Diagnostics, meaning they are not backed by specific collateral. They will rank equally with the company's other existing and future senior unsecured debt.

The indenture includes a provision that upon a 'change of control triggering event' (as defined in the indenture), Quest Diagnostics will be required to make an offer to purchase the notes at a price of 101% of their principal amount, plus any accrued and unpaid interest.